ER、PR、HER-2及Ki-67表达与乳腺癌患者新辅助化疗后病理完全缓解的相关性分析  

Correlation between the Expression of ER,PR,HER-2 and Ki-67 and Pathological Complete Remission in Breast Cancer Patients after Neoadjuvant Chemotherapy

作　　者：宋莹[1] 李江龙 SONG Ying;LI Jianglong(Department of Clinical Laboratory,Jiangxi Cancer Hospital,Nanchang 330029,China;不详)

机构地区：[1]江西省肿瘤医院医学检验科,江西南昌330029 [2]江西省肿瘤医院乳腺肿瘤外科,江西南昌330029

出　　处：《中国医学创新》2024年第27期139-143,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(20213582)。

摘　　要：目的:分析雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)及Ki67抗原(Ki-67)表达与乳腺癌患者新辅助化疗后病理完全缓解(pathologic complete response,pCR)的相关性。方法:回顾性分析2022年1月—2023年12月在江西省肿瘤医院行新辅助化疗的200例乳腺癌患者的临床资料,根据化疗后手术病理标本,分为pCR组68例和非pCR组132例,比较两组临床资料和ER、PR、HER-2及Ki-67表达,多因素logistic回归分析ER、PR、HER-2及Ki-67表达与pCR的相关性。结果:单因素分析显示,pCR组临床分期Ⅱ期比例高于非pCR组,ER、PR阴性比例均高于非pCR组,HER-2阳性比例高于非pCR组,Ki-67≥20%比例高于非pCR组,差异均有统计学意义(P<0.05)。多因素logistic回归分析显示,临床分期Ⅲ期、ER阳性、PR阳性、HER-2阴性、Ki-67<20%是乳腺癌新辅助化疗后pCR的危险因素(P<0.05)。结论:ER、PR、HER-2及Ki-67表达是乳腺癌患者新辅助化疗后pCR的影响因素,可为临床治疗提供依据。Objective:To analyze the correlation between the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(HER-2)and Ki67 antigen(Ki-67)and pathological complete remission(pCR)in breast cancer patients after neoadjuvant chemotherapy.Method:The clinical data of 200 breast cancer patients who received neoadjuvant chemotherapy in Jiangxi Cancer Hospital from January 2022 to December 2023 were analyzed retrospectively.According to the surgical and pathological results after neoadjuvant chemotherapy,the patients were divided into pCR group(68 cases)and non-pCR group(132 cases).Clinical data and the expression of ER,PR,HER-2 and Ki-67 in the two groups were compared.The correlation between the expression of ER,PR,HER-2 and Ki-67 and pCR was analyzed by multivariate logistic regression analysis.Result:Univariate analysis found that the proportion of clinical stageⅡin pCR group was higher than that in non-PCR group,the proportions of ER and PR negative were higher than those in non-PCR group,the proportion of HER-2 positive was higher than that in non-PCR group,and the proportion of Ki-67≥20%was higher than that in non-PCR group,with statistical significance(P<0.05).Multivariate logistic regression analysis found that clinical stageⅢ,ER positive,PR positive,HER-2 negative and Ki-67<20%were risk factors for pCR after neoadjuvant chemotherapy for breast cancer(P<0.05).Conclusion:The expressions of ER,PR,HER-2 and Ki-67 are the influencing factors of pCR in breast cancer patients after neoadjuvant chemotherapy,which provide a basis for clinical treatment.

关 键 词：乳腺癌 雌激素受体 孕激素受体 人表皮生长因子受体-2 KI67抗原 新辅助化疗 病理完全缓解 

分 类 号：R737.9[医药卫生—肿瘤]